Altamira Therapeutics Announces Closing Of Up To $12.0 Million Public Offering
Hamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- <li /> $4 million upfront with up to an additional $8 million of aggregate gro ...
Vancouver3 天
Vancouver biotech inks $800M partnership with Novo Nordisk
NanoVation Therapeutics, a Vancouver company co-founded by biotech magnate Pieter Cullis, has struck a partnership with ...
BCBusiness3 天
UBC’s NanoVation Therapeutics inks US$600 million deal with Novo Nordisk
The agreement with NanoVation marks the second big recent deal that a B.C. biotech startup has struck with the Danish ...
Researchers identify potential new strategy to slow the development of liver fibrosis
A study led by Manuel Vázquez Carrera, group leader at the Diabetes and Associated Metabolic Diseases Networking Biomedical ...
News Medical5 天
Activation of PPARβ/δ-AMPK pathway shown to slow liver fibrosis development
A study led by Manuel Vázquez Carrera, group leader at the Diabetes and Associated Metabolic Diseases Networking Biomedical ...
Endovascular Today6 天
Delcath Systems Hepzato Kit for mUM Evaluated in Subgroup Analysis of FOCUS Trial
Delcath Systems, Inc. announced the presentation of new subgroup analysis data from the phase 3 FOCUS trial of Hepzato Kit (m ...
Le Lézard6 天
Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO ...
Delcath Systems, Inc. , an interventional oncology company focused on liver-directed cancer therapies, today announced the presentation of new subgroup analysis data from the FOCUS Phase 3 trial of ...
Original paper10 天
Progression patterns in patients with advanced hepatocellular carcinoma treated with local ...
The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China ...
Researchers compare tumor characteristics, survival outcome of different bile duct cancers
Cholangiocarcinoma (CCA) or bile duct cancer, is a rare, aggressive liver cancer with a poor prognosis, which occurs mostly ...